Lead Product(s) : CIT-013
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Bom Brabant Ventures
Deal Size : $21.0 million
Deal Type : Financing
Details : The proceeds will be used to advance the pre-clinical and clinical development of Citryll’s CIT-013 therapeutic antibody, an inhibitor of neutrophil extracellular traps (NETs) and their formation (NETosis).
Product Name : CIT-013
Product Type : Antibody
Upfront Cash : Undisclosed
February 07, 2020
Lead Product(s) : CIT-013
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Bom Brabant Ventures
Deal Size : $21.0 million
Deal Type : Financing